Skip to content
RYTMRhythm Pharmaceuticals, Inc.

Earnings

When Rhythm Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

43 quarters. Mar 31, 2016 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, before the open

Thu, Feb 25, 2027in 100 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 25 – Mar 5

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$57.25M
Revenue, change from a year earlier: Q3 2026 +79.6%, Q2 2026 +46.9%, Q1 2026 +83.8%, Q4 2025 +36.9%
Net income
-$47.51M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$92.13M+79.6% vs Q3 2025

Latest results

  1. Q3 2026Nov 3, 2026, before the openThe release7.8%by the close of Nov 3
    Revenue
    $92.13M
    +79.6%
    Net income
    -$41.37M
    N/M
    EPS
    -$0.61
    N/M
    Read · nothing to show
  2. Q2 2026Aug 4, 2026, before the openThe release+2.8%by the close of Aug 4
    Revenue
    $71.26M
    +46.9%
    Net income
    -$49.30M
    N/M
    EPS
    -$0.73
    N/M
  3. Q1 2026May 5, 2026, before the openThe release+8.2%by the close of May 5
    Revenue
    $60.11M
    +83.8%
    Net income
    -$55.64M
    N/M
    EPS
    -$0.83
    N/M
  4. Q4 2025Feb 26, 2026, before the openThe release0.8%by the close of Feb 26
    Revenue
    $57.25M
    +36.9%
    Net income
    -$47.51M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · pre-marketNov 3, 202634 d10-Q$92.13M+79.6%-$0.617.8%
Q2 2026Jun 30, 2026Aug 4, 2026 · pre-marketAug 4, 202635 d10-Q$71.26M+46.9%-$0.73+2.8%
Q1 2026Mar 31, 2026May 5, 2026 · pre-marketMay 5, 202635 d10-Q$60.11M+83.8%-$0.83+8.2%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · pre-marketFeb 26, 202657 d10-K$57.25M+36.9%—0.8%
Q3 2025Sep 30, 2025Nov 4, 2025 · pre-marketNov 4, 202535 d10-Q$51.30M+54.3%-$0.827.7%
Q2 2025Jun 30, 2025Aug 5, 2025 · pre-marketAug 5, 202536 d10-Q$48.50M+66.8%-$0.751.9%
Q1 2025Mar 31, 2025May 7, 2025 · pre-marketMay 7, 202537 d10-Q$32.70M+25.9%-$0.81+3.1%
FY 2024
Q4 2024derivedDec 31, 2024Feb 26, 2025 · pre-marketFeb 28, 202559 d10-K$41.83M+72.6%—+4.4%
Q3 2024Sep 30, 2024Nov 5, 2024 · after-hoursNov 6, 202437 d10-Q$33.25M+47.8%-$0.73+11.4%
Q2 2024Jun 30, 2024Aug 6, 2024 · pre-marketAug 6, 202437 d10-Q$29.08M+51.3%-$0.55—
Q1 2024Mar 31, 2024May 7, 2024 · pre-marketMay 7, 202437 d10-Q$25.97M+126.4%-$2.3510.3%
Earlier years, FY 2016 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026069485
10-QAug 4, 2026052533
10-QMay 5, 2026030549
10-KFeb 26, 2026012399
10-QNov 4, 2025106264
10-QAug 5, 2025010302
10-QMay 7, 2025006765
10-KFeb 28, 2025001889
10-QNov 6, 2024014532
10-QAug 6, 2024011101

Provenance

ProvenanceData status and checks

Rhythm Pharmaceuticals, Inc. · CIK 1649904 · Engraved from SEC EDGAR